The researchers excluded patients already taking an angiotensin-receptor blocker
or angiotensin-converting enzyme inhibitor.
Patients who cannot tolerate ACEI can substitute an angiotensin-receptor blocker
Effects of the angiotensin-receptor blocker
telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
proteinuria or symptomatic left ventricular systolic dysfunction despite treatment with and ACE inhibitor or an angiotensin-receptor blocker
alone," said Dr.
A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure.
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker
The angiotensin-receptor blocker
valsartan also failed to prevent cardiovascular events in the same trial, but it did induce an unexpected relative reduction of 14% in the incidence of diabetes, according to the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study Group.
A Your doctor has probably recommended that you take a statin to lower cholesterol, low-dose aspirin to reduce the risk of stroke and second heart attack, a beta-blocker, and an angioten-sin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker
If you cannot tolerate ACE inhibitors, your doctor may recommend an angiotensin-receptor blocker
ONTARGET was designed to answer two clinically relevant questions: Is the angiotensin-receptor blocker
(ARB) telmisartan an effective alternative to ramipril in the 20%-30% of patients who can't tolerate an angiotensin-converting enzyme (ACE) inhibitor because of cough, angioedema, or other side effects?
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted unanimously against approving the angiotensin-receptor blocker
for reducing the risk of MI, stroke, cardiovascular deaths, or hospitalization for heart failure in patients 55 years or older at high risk of developing major cardiovascular events.
To start treatment according the algorithm, which called for a low-dose (half tablet) of a marketed formulation that combined a diuretic with either an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker
, physicians could choose among 11 formulations that were on the Canadian market at the time the study began.